Solutions for Tumor Angiogenesis
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides comprehensive solutions for the study of tumor angiogenesis, helping researchers successfully achieve their research goals.
Rapid tumor growth can face hypoxia, nutrient deprivation, and space pressure. Tumors reengineer the tumor microenvironment (TME) so that the TME favors continued tumor growth. On the one hand, cells in the TME communicate and interact with each other through autocrine and paracrine signaling molecules, turning on the "switch" of tumor angiogenesis and initiating tumor angiogenesis. On the other hand, poor TMEs such as hypoxia, acidity, and hypertonicity also perform "predominant selection" on tumors. Selected malignancies accelerate tumor angiogenesis, promote tumor growth, and increase tumor invasiveness and risk of metastasis. Therefore, tumor angiogenesis plays a key role in the occurrence and development of tumors, and tumor vascular density is directly related to prognosis. Meanwhile, tumor angiogenesis is a complex multi-step process, regulated by multiple factors, and is the result of an imbalance between stimulatory and inhibitory factors. More than 30 angiogenic factors have been reported, such as VEGF, bFGF, pDGF, HGF, TNF, IL-8.
A century ago, pioneers in angiogenesis research observed tumor growth accompanied by increased blood vessels. In 1971, the strategy of treating tumors by inhibiting angiogenesis was first proposed. At present, targeted therapy for tumor angiogenesis has become one of the effective treatment methods, and in the context of advocating "precision medicine", the research on anti-angiogenesis therapy is heating up. At the same time, basic research has continuously discovered more factors closely related to tumor angiogenesis. The accumulation of clinical experience with anti-angiogenic therapy brings many new problems, such as drug resistance. Alfa Oncology is developing various technologies to explore and solve the above problems, hoping to break through these problems and provide methods or drug guidance for clinical treatment of anti-angiogenesis.
As far as angiogenesis is concerned, two-dimensional cell culture cannot form a three-dimensional vascular system, so it is not suitable for the study of angiogenesis, collateral association and remodeling. To this end, we have started to establish a three-dimensional culture model (3D culture model) and successfully induced the formation of blood vessels from endothelial cells. Advances in the technique of culturing vascular endothelial cells in vitro and experimental methods of angiogenesis have promoted the research progress of angiogenesis. Since then, anti-angiogenic therapy has been aided in various aspects, such as attacking existing tumor blood vessels; neutralizing angiogenesis-promoting factors, thereby inhibiting angiogenesis; using endogenous or exogenous angiogenesis-inhibiting factors to inhibit angiogenesis.
Imaging techniques can be non-invasive, fast, and in vivo to evaluate tumor angiogenesis and anti-angiogenesis efficacy and display the whole picture of tumors, with high specificity and high sensitivity. Help us in our efforts to find suitable targets to block and destroy tumor angiogenesis, and develop effective anti-tumor angiogenesis drugs.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.